<DOC>
	<DOCNO>NCT01842581</DOCNO>
	<brief_summary>The purpose study evaluate Rifaximin alone Rifaximin plus Lactulose delay onset hepatic encephalopathy ( HE ) cirrhotic subject previous episode HE .</brief_summary>
	<brief_title>The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Male nonpregnant , nonlactating female &gt; /= 18 year In remission demonstrate overt HE Have one episodes overt HE associate cirrhosis last 6 month Subject close family member personal contact familiar subject 's HE provide continue oversight subject willing perform caregiver conduct trial HIV History Tuberculosis infection Chronic respiratory insufficiency Current infection receive antibiotic Renal insufficiency require dialysis Active spontaneous bacterial peritonitis infection Intestinal obstruction inflammatory bowel disease Active malignancy within last 5 year Current GI bleed history GI hemorrhage ( within last 3 month Anemia Scheduled receive liver transplant within 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Liver Failure</keyword>
	<keyword>Hepatic Insufficiency</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Rifaximin</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>